Asset Details
Do you wish to reserve the book?
Nuclear EGFR in breast cancer suppresses NK cell recruitment and cytotoxicity
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Nuclear EGFR in breast cancer suppresses NK cell recruitment and cytotoxicity
Do you wish to request the book?
Nuclear EGFR in breast cancer suppresses NK cell recruitment and cytotoxicity
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Nuclear EGFR in breast cancer suppresses NK cell recruitment and cytotoxicity
2025
Overview
Natural Killer (NK) cells can target and destroy cancer cells, yet tumor microenvironments typically suppress NK cell recruitment and cytotoxicity. The epidermal growth factor receptor (EGFR) is a potent oncogene that can activate survival, migration, and proliferation pathways, and clinical data suggests it may also play an immunomodulating role in cancers. Recent work has demonstrated a novel role for nuclear EGFR (nEGFR) in regulating transcriptional events unique from the kinase domain. Using a novel peptide therapeutic (cSNX1.3) that inhibits retrograde trafficking of EGFR and an EGFR nuclear localization mutant, we discovered that nEGFR suppresses NK cell recruitment and cytotoxicity. RNA-Seq analysis of breast cancer cells treated with cSNX1.3 or modified to lack a nuclear localization sequence (EGFR
ΔNLS
) revealed the EGF-dependent induction of NK activating receptor ligands, while kinase inhibition by erlotinib did not impact these genes. NanoString analysis of tumor-bearing WAP-TGFα transgenic mice treated with cSNX1.3 demonstrated an increase in immune cell populations and activating genes. Additionally, immunohistochemistry confirmed an increase in NK cells upon cSNX1.3 treatment. Finally, cSNX1.3 treatment was found to enhance NK cell recruitment and cytotoxicity in vitro. Together, the data demonstrate a unique immunomodulatory role for nEGFR.
Publisher
Nature Publishing Group UK,Nature Publishing Group
Subject
/ 38/91
/ 45/70
/ 64/110
/ 96/106
/ Animals
/ Breast Neoplasms - drug therapy
/ Breast Neoplasms - immunology
/ Breast Neoplasms - metabolism
/ Breast Neoplasms - pathology
/ Epidermal growth factor receptors
/ Female
/ Humans
/ Killer Cells, Natural - drug effects
/ Killer Cells, Natural - immunology
/ Killer Cells, Natural - metabolism
/ Medicine
/ Mice
/ Oncology
/ Transforming growth factor-a
/ Tumor Microenvironment - immunology
/ Tumors
